A phase 1 study of SGN-CD123Ain patients with relapsed or refractory acute myeloid leukemia (AML)
The goal of this clinical research study is to find the highest tolerable dose of the study drug SGN-CD123A that can be given to patients with AML. The safety of this drug will also be studied. Researchers also want to learn about any effects the drug may have on AML. This is the first study using SGN-CD123A in humans.
Treatment Location: N/A
IRB Review and Approval Date: 01/19/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: